The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult). These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes. An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease. LPI (LP Information)' newest research report, the “Human Microbiome Industry Forecast” looks at past sales and reviews total world Human Microbiome sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Microbiome sales for 2023 through 2029. With Human Microbiome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Microbiome industry. This Insight Report provides a comprehensive analysis of the global Human Microbiome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Microbiome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Microbiome market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Microbiome and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Microbiome. The global Human Microbiome market size is projected to grow from US$ 376.5 million in 2022 to US$ 1559.6 million in 2029; it is expected to grow at a CAGR of 22.5% from 2023 to 2029. At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share. This report presents a comprehensive overview, market shares, and growth opportunities of Human Microbiome market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Gastrointestinal Tract Human Micobiome Urogenital Tract Human Micobiome Others Segmentation by application Treatment Diagnosis This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Vedanta Seres Therapeutics Second Genome Rebiotix ActoGeniX Enterome BioScience AvidBiotics 4D Pharma Research Ltd Enterologics Metabogen Metabiomics Ritter Pharmaceuticals Osel Symberix Miomics Symbiotix Biotherapies MicroBiome Therapeutics LLC
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Human Microbiome Market Size 2018-2029 2.1.2 Human
